CC BY-NC-ND 4.0 · Arquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery 2024; 43(01): e73-e75
DOI: 10.1055/s-0043-1776700
Case Report

Macroprolactinoma in a 14-Year-Old Girl in the Northeast of Iran: A Case Report

Macroprolactinoma em uma garota de 14 anos no nordeste do Irã: Relato de caso
Habibe Sadat Shakeri
1   North Khorasan University of Medical Sciences, Bojnurd, Iran
1   North Khorasan University of Medical Sciences, Bojnurd, Iran
Alireza Monemi
1   North Khorasan University of Medical Sciences, Bojnurd, Iran
› Institutsangaben
Funding The authors declare they have received no funding pertaining to the present article.


Prolactinoma is frequently found not only in females but also in males with abnormal reproductive and/or sexual function. Patients typically complain about amenorrhea and infertility because of anovulation. Approximately 15% to 20% of cases of secondary amenorrhea are caused by prolactinemia. Galactorrhea may occur simultaneously, before or after menstrual disorders, and sometimes it may not be clinically obvious, or only detected by breast examination. We reported a case of a 14-year-old girl who presented primary amenorrhea accompanied by frequent headaches and blurred vision. Hormonal tests showed severe hyperprolactinemia (prolactin [PRL] concentration: 1,570 ng/ml). Further tests confirmed a mass in the pituitary with an extension to the left parasellar and suprasellar regions. Some parts of the sella turcica tumor were removed by transcranial surgery. During the follow-up, the clinicopathological examinations revealed the patient had hyperprolactinemia. Clinicians should be aware of the diagnostic and therapeutic problems regarding the management of hyperprolactinemia.


O prolactinoma é frequentemente encontrado não apenas em mulheres, mas também em homens com funç ão reprodutiva e/ou sexual anormal. Os pacientes geralmente se queixam de amenorreia e infertilidade devido à anovulaç ão. Aproximadamente 15% a 20% dos casos de amenorreia secundária são causados por prolactinoma. A galactorreia pode ocorrer simultaneamente, antes ou depois dos distúrbios menstruais, e às vezes pode não ser clinicamente óbvia ou ser detectada apenas pelo exame das mamas. Relatamos o caso de uma menina de 14 anos que apresentou amenorreia primária acompanhada de dores de cabeça frequentes e visão turva. Os testes hormonais mostraram hiperprolactinemia grave (concentraç ão de prolactina [PRL]: 1.570 ng/ml).Outros exames confirmaram uma massa na hipófise com extensão para as regiões parasselar e suprasselar esquerda. Algumas partes do tumor da sela turca foram removidas por cirurgia transcraniana. Durante o acompanhamento, os exames clinicopatológicos revelaram que o paciente apresentava hiperprolactinemia. Os médicos devem estar cientes dos problemas diagnósticos e terapêuticos relativos ao manejo da hiperprolactinemia.


Habibe Sadat Shakeri and Alireza Monemi participated in the conception, design, and interpretation of data; Samaneh Mollazadeh drafted the manuscript; the final version of the manuscript was approved by all authors.

Ethical Approval

All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent to Participate

Informed consent was obtained from the patient included in the study.


Eingereicht: 06. Juli 2020

Angenommen: 09. März 2021

Artikel online veröffentlicht:
28. Februar 2024

© 2024. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

  • References

  • 1 Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol 2014; 170 (06) R213-R227
  • 2 Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27 (05) 485-534
  • 3 Moraes AB, Silva CM, Vieira Neto L, Gadelha MR. Giant prolactinomas: the therapeutic approach. Clin Endocrinol (Oxf) 2013; 79 (04) 447-456
  • 4 Czyzyk A, Kurzawa R. Hyperprolactinemia associated with macroprolactinoma in a 17-year-old: A case report. Case Rep Womens Health 2019; 22: e00111
  • 5 Wu ZB, Yu CJ, Su ZP, Zhuge QC, Wu JS, Zheng WM. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg 2006; 104 (01) 54-61
  • 6 Delgrange E, Raverot G, Bex M. et al. Giant prolactinomas in women. Eur J Endocrinol 2013; 170 (01) 31-38
  • 7 Brue T, Delemer B. French Society of Endocrinology (SFE) work group on the consensus on hyperprolactinemia. Diagnosis and management of hyperprolactinemia: expert consensus - French Society of Endocrinology. Ann Endocrinol (Paris) 2007; 68 (01) 58-64
  • 8 McCutcheon IE. Pituitary adenomas: Surgery and radiotherapy in the age of molecular diagnostics and pathology. Curr Probl Cancer 2013; 37 (01) 6-37